Sigma-Aldrich And MorphoSys AG To Collaborate For Developing And Distributing Recombinant Research Antibodies [SIAL]
2/27/2008 3:11:39 AM Wednesday, MorphoSys AG, a biotechnology company, announced the signing of collaboration agreement with Sigma-Aldrich (SIAL) to design, produce and distribute unique recombinant research antibodies.
Under the collaboration, MorphoSys AbD Serotec unit would develop and qualify unique antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich.
MorphoSys said that Sigma-Aldrich would offer the HuCAL-based recombinant research antibodies for use in research applications through its powerful and unique online sales platforms Antibody Explorer and Your Favorite Gene Search.
HuCAL GOLD is a phage-display library developed for the in-vitro generation of highly specific and fully human antibodies to targets that have previously been difficult to probe with standard antibody-generation technologies, MorphoSys added.
David Smoller, President of Sigma-Aldrich's Research Biotech business unit, commented, “In conjunction with Sigma-Aldrich's standard content generation capabilities, the powerful HuCAL-based recombinant antibody technology is expected to allow the research community to reach its goal of a binder for every gene and one-day even protein in the human body.''
Simon Moroney, Chief Executive Officer of MorphoSys AG, observed, “The contract supports MorphoSys's goal to introduce a growing number of HuCAL research antibodies into the market, and will further increase AbD Serotec's presence and the acceptance of recombinant research antibodies in the research community alike.''
Sigma-Aldrich closed Tuesday's regular trading session at $56.32, down $0.30 or 0.53%. |
